For example, low-dose methotrexate used in cardiovascular inflammatory reduction trial (CIRT) did not lower IL-1β, IL-6, CRP levels, or reduce cardiovascular events in patients with stable atherosclerosis [41]. This evidence concerns the gene CRP and atherosclerosis.